Affimed N.V. (AFMD)
After hours:
| Previous Close | 3.1500 |
| Open | 3.0800 |
| Bid | 2.9600 x 3200 |
| Ask | 3.0200 x 2900 |
| Day's Range | 2.9900 - 3.0900 |
| 52 Week Range | 2.2300 - 7.3500 |
| Volume | |
| Avg. Volume | 1,005,445 |
| Market Cap | 449.51M |
| Beta (5Y Monthly) | 2.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated data at a scientific conference in the fourth quarter of 2022AFM24: Studies continue to enroll; data updates expected at scientific conferences in the second half of 2022AFM28: Following interactions with FDA, strategic decision to focus early clinical development in non-U.S. jurisdictions; clinica
- GlobeNewswire
Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call,
- GlobeNewswire
Affimed Establishes Scientific Advisory Board
Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncologyScientific Advisory Board to provide guidance on the Company’s development strategy across assets and assessment of emerging technologies HEIDELBERG, Germany, June 30, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to
